Source: Tech – South China Morning PostChina’s rise in biotech innovation offers the world a potentially cheaper alternative to costly healthcare products from Western suppliers, but geopolitical tensions remain a major challenge for the country’s globalisation efforts, according to a local investor in the sector.
“We can lower the cost of healthcare and benefit more people through technological innovation and efficiency improvement,” Da Liu, managing director of CR-CP Life Science Fund, said in an interview with the Post earlier…Read More